AveXis Brings $55M Gene Therapy Factory, 200 Jobs to Durham
g925518.jpg
Patient death in Novartis gene therapy trial unrelated to treatment, subsidiary says - MedCity News
AveXIS Announcement – Utah Program for Inherited Neuromuscular Disorders
AveXis Reports Topline Results from Phase 1 Trial of SMA Type 1 Gene Therapy - Drug Discovery and Development
AveXis's House Of Cards: Dubious Trials, Drug Lawsuit And Fraud Allegations - Strong Sell With 94% Downside (NASDAQ:AVXS) | Seeking Alpha
Another Zolgensma red flag, another delay in data reporting at Novartis' AveXis | Fierce Pharma
Novartis-bound AveXis posts early look at data from pivotal SMA gene therapy trial | Fierce Biotech
AveXis Presents Promising Trial Results of Gene Therapy for SMA Type 1
AveXis nabs breakthrough tag for gene therapy, plans pivotal trial start in 2017 | Fierce Biotech
AveXis Brings $55M Gene Therapy Factory, 200 Jobs to Durham
AveXis' Lone-Drug Bubble - Much Ado About Nothing? (NASDAQ:AVXS) | Seeking Alpha
AveXis Gene Therapy Manufacturing Facility, North Carolina, USA
AveXis Inc.: Buy at the High? | The Motley Fool
AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA
AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA
AveXis Doubles Down, Adding 200 Jobs, $60M to Durham Gene Therapy Facility | North Carolina Biotechnology Center
AveXis' Lone-Drug Bubble - Much Ado About Nothing? (NASDAQ:AVXS) | Seeking Alpha
AveXis Receives FDA Breakthrough Therapy Designation for AVXS-101 (Gene Therapy) for SMA - Cure SMA
A 2nd Patient Death Reported in Novartis' Gene Therapy Trial | BioSpace
AveXis Knew of 'Manipulated' Data in Zolgensma Application, FDA Says
Promising results in phase 1 SMA gene therapy trial - Muscular Dystrophy Association
FDA Places Partial Clinical Hold on Some Trials of Novartis Gene Therapy
AveXis Receives FDA Approval of Zolgensma, a Gene Therapy, for Spinal Muscular Atrophy for Patients Under Two Years of Age - Cure SMA
25 Up-and-Coming Gene Therapies of 2019
AveXis steps up gene therapy pursuit of Biogen's SMA pathfinder | Fierce Biotech
The world's most expensive drug?
